Caribou Biosciences (CRBU) Net Cash Flow (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Net Cash Flow data on file, last reported at -$319000.0 in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$319000.0, down 102.43% year-over-year; the trailing twelve-month figure through Mar 2026 was -$17.4 million (up 13.01% YoY), and the FY2025 annual result was -$3.9 million, up 88.7% from the prior year.
• Net Cash Flow declined to -$319000.0 in Q1 2026 per CRBU's latest filing, from $1.2 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $37.9 million in Q3 2023 and troughed at -$92.8 million in Q1 2022.
• A 5-year average of -$13.4 million and a median of -$5.9 million in 2024 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow tumbled 185.75% in 2024, then surged 844.84% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$23.7 million in 2022, then tumbled by 122.75% to -$52.9 million in 2023, then jumped by 70.36% to -$15.7 million in 2024, then soared by 107.71% to $1.2 million in 2025, then plunged by 126.41% to -$319000.0 in 2026.
• Business Quant data shows CRBU's Net Cash Flow at -$319000.0 in Q1 2026, $1.2 million in Q4 2025, and -$14.1 million in Q3 2025.